SI3221349T1 - Humanizirano tau protitelo pri alzheimerjevi bolezni - Google Patents

Humanizirano tau protitelo pri alzheimerjevi bolezni

Info

Publication number
SI3221349T1
SI3221349T1 SI201531480T SI201531480T SI3221349T1 SI 3221349 T1 SI3221349 T1 SI 3221349T1 SI 201531480 T SI201531480 T SI 201531480T SI 201531480 T SI201531480 T SI 201531480T SI 3221349 T1 SI3221349 T1 SI 3221349T1
Authority
SI
Slovenia
Prior art keywords
alzheimer
disease
tau antibodies
humanized tau
humanized
Prior art date
Application number
SI201531480T
Other languages
English (en)
Inventor
Michal Novak
Eva Kontsekova
Branislav Kovacech
Rostislav Skrabana
Original Assignee
Axon Neuroscience Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Neuroscience Se filed Critical Axon Neuroscience Se
Publication of SI3221349T1 publication Critical patent/SI3221349T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation
SI201531480T 2014-11-19 2015-11-18 Humanizirano tau protitelo pri alzheimerjevi bolezni SI3221349T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081809P 2014-11-19 2014-11-19
PCT/IB2015/002610 WO2016079597A1 (en) 2014-11-19 2015-11-18 Humanized tau antibodies in alzheimer's disease
EP15837211.0A EP3221349B1 (en) 2014-11-19 2015-11-18 Humanized tau antibodies in alzheimer's disease

Publications (1)

Publication Number Publication Date
SI3221349T1 true SI3221349T1 (sl) 2021-02-26

Family

ID=55411706

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531480T SI3221349T1 (sl) 2014-11-19 2015-11-18 Humanizirano tau protitelo pri alzheimerjevi bolezni

Country Status (24)

Country Link
US (3) US10160799B2 (sl)
EP (2) EP3221349B1 (sl)
JP (3) JP6830061B2 (sl)
KR (1) KR20170126855A (sl)
CN (1) CN107428820B (sl)
AU (2) AU2015348012B2 (sl)
BR (1) BR112017010498A2 (sl)
CA (1) CA2966964A1 (sl)
CY (1) CY1123746T1 (sl)
DK (1) DK3221349T3 (sl)
ES (1) ES2848376T3 (sl)
HK (1) HK1244495A1 (sl)
HR (1) HRP20210124T1 (sl)
HU (1) HUE053239T2 (sl)
IL (2) IL251921B (sl)
LT (1) LT3221349T (sl)
MX (2) MX2017006663A (sl)
PL (1) PL3221349T3 (sl)
PT (1) PT3221349T (sl)
RS (1) RS61431B1 (sl)
RU (2) RU2730668C2 (sl)
SG (1) SG11201703237VA (sl)
SI (1) SI3221349T1 (sl)
WO (1) WO2016079597A1 (sl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201707855YA (en) 2013-03-13 2017-10-30 Prothena Biosciences Ltd Tau immunotherapy
SG10202007103TA (en) 2014-11-05 2020-09-29 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
RU2730668C2 (ru) * 2014-11-19 2020-08-24 Аксон Ньюросайенс Се Гуманизированные тау-антитела при болезни альцгеймера
PE20190261A1 (es) * 2016-05-02 2019-02-25 Prothena Biosciences Ltd Anticuerpos que reconocen tau
CA3022765A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
CN109415432B (zh) 2016-05-02 2022-07-08 普罗塞纳生物科学有限公司 Tau免疫疗法
MA47499A (fr) * 2017-02-17 2019-12-25 Denali Therapeutics Inc Anticorps anti-tau et leurs procédés d'utilisation
CN110418804A (zh) * 2017-03-28 2019-11-05 扬森疫苗与预防公司 与tau特异性地结合的结合分子
BR112019022906A2 (pt) 2017-05-02 2020-05-26 Prothena Biosciences Limited Anticorpos que reconhecem tau
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
WO2019048017A1 (en) * 2017-09-07 2019-03-14 Danmarks Tekniske Universitet METHODS FOR REMOVING NOX FROM A GAS STREAM CONTAINING MORE THAN ONE GAS COMPOUND
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
WO2019161384A1 (en) * 2018-02-19 2019-08-22 New York University Tau single domain antibodies
AU2019244481A1 (en) * 2018-03-28 2020-10-01 Axon Neuroscience Se Antibody-based methods of detecting and treating Alzheimer's disease
WO2019213612A1 (en) * 2018-05-03 2019-11-07 Washington University Methods of diagnosing and treating based on site-specific tau phosphorylation
AU2018446059A1 (en) * 2018-10-17 2021-05-20 The University Of Queensland Methods and compositions for treating tauopathies
JOP20210098A1 (ar) * 2018-11-08 2023-01-30 Prothena Biosciences Ltd أجسام مضادة تتعرف على تاو
CU20210073A7 (es) * 2019-03-03 2022-04-07 Prothena Biosciences Ltd Anticuerpos que se unen dentro de la región de unión a microtúbulos de tau definida por cdrs
TW202115112A (zh) * 2019-06-27 2021-04-16 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
CN114340654A (zh) 2019-09-09 2022-04-12 阿克松神经系统科学公司 阿尔茨海默病和轻度认知障碍的生物标志物和治疗
WO2021173962A1 (en) * 2020-02-28 2021-09-02 Genemo, Inc. Methods and materials for diagnosis and treatment of neuronal disorder
EP4217063A1 (en) * 2020-09-22 2023-08-02 Kathleen E. Clarence-Smith Pharmaceutical combination for the treatment of human hypocholinergic disorders
CN112625129B (zh) * 2020-11-26 2022-05-20 江苏荃信生物医药股份有限公司 一种抗人白介素23及包含其的试剂盒及其检测方法
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2024036005A1 (en) * 2022-08-10 2024-02-15 Nkmax Co., Ltd. Method of treating alzheimer's disease with expanded natural killer cells

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HU196394B (en) 1986-06-27 1988-11-28 Richter Gedeon Vegyeszet Process for preparing 2-halogenated ergoline derivatives
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Noble hydrazonic history of anthracycline and methods for their preparation
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP0652775B1 (en) 1992-07-27 2000-04-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Targeting of liposomes to the blood-brain barrier
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CA2142190C (fr) 1995-02-14 1998-01-27 Marc Lessard Conduite d'exfiltration d'air use
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
CN1151842C (zh) 1995-07-27 2004-06-02 基因技术股份有限公司 稳定等渗的冻干蛋白制剂
PT871490E (pt) 1995-12-22 2003-07-31 Bristol Myers Squibb Co Ligantes de hidrazona ramificada
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
SI0994728T1 (sl) 1997-04-09 2009-02-28 Intellect Neurosciences Inc Rekombinantna protitelesa, specifična za beta-amiloidne konce, kodirana z DNA ter postopki za njihovo uporabo
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
AU7653100A (en) 1999-09-09 2001-04-10 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. A minimal tau peptide for the nucleation of paired helical filaments
IL151378A0 (en) 2000-02-24 2003-04-10 Univ Washington Humanized antibodies that sequester amyloid beta peptide
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
WO2002017930A2 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
WO2003009815A2 (en) 2001-07-25 2003-02-06 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
KR20040054669A (ko) 2001-08-03 2004-06-25 글리카트 바이오테크놀로지 아게 항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체
CN100423777C (zh) 2001-10-25 2008-10-08 杰南技术公司 糖蛋白组合物
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
ATE391781T1 (de) 2002-07-12 2008-04-15 Axon Neuroscience Transgenes tier welches das trunkierte alzheimer tau protein exprimiert
HUE027549T2 (hu) 2002-07-31 2016-10-28 Seattle Genetics Inc Hatóanyagot tartalmazó konjugátumok és alkalmazásuk rák, autoimmun betegség vagy fertõzéses betegség kezelésére
AU2003302676A1 (en) 2002-12-03 2004-06-23 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
MXPA05006940A (es) 2002-12-24 2006-02-22 Neurochem Int Ltd Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
WO2005025511A2 (en) 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
KR101192496B1 (ko) 2003-11-06 2012-10-18 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
RU2412947C2 (ru) 2004-09-23 2011-02-27 Дженентек, Инк. Антитела, сконструированные на основе цистеинов, и их конъюгаты
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
TW201216985A (en) * 2010-10-07 2012-05-01 Ac Immune Sa Pharmaceutical composition
US20130295021A1 (en) * 2010-10-11 2013-11-07 Feng Chen Human anti-tau antibodies
CN104185640B (zh) 2011-09-19 2018-07-20 阿克松神经系统科学公司 阿尔茨海默病中的tau蛋白介导病变的基于蛋白质的疗法和诊断
KR102132041B1 (ko) * 2012-04-05 2020-07-09 에이씨 이뮨 에스.에이. 인간화된 타우 항체
MX2015008024A (es) * 2012-12-21 2016-08-08 Biogen Int Neuroscience Gmbh Anticuerpos anti-tau humanos.
RU2730668C2 (ru) * 2014-11-19 2020-08-24 Аксон Ньюросайенс Се Гуманизированные тау-антитела при болезни альцгеймера

Also Published As

Publication number Publication date
HK1244495A1 (zh) 2018-08-10
WO2016079597A8 (en) 2020-07-02
IL251921A0 (en) 2017-06-29
KR20170126855A (ko) 2017-11-20
JP6830061B2 (ja) 2021-02-17
CA2966964A1 (en) 2016-05-26
RU2730668C2 (ru) 2020-08-24
BR112017010498A2 (pt) 2017-12-26
EP3221349B1 (en) 2020-11-04
JP2018502558A (ja) 2018-02-01
EP3786182A1 (en) 2021-03-03
HRP20210124T1 (hr) 2021-03-19
EP3221349A1 (en) 2017-09-27
US20210009666A1 (en) 2021-01-14
IL251921B (en) 2021-07-29
US10745469B2 (en) 2020-08-18
PT3221349T (pt) 2021-01-21
SG11201703237VA (en) 2017-06-29
DK3221349T3 (da) 2021-01-04
MX2017006663A (es) 2017-08-21
LT3221349T (lt) 2021-02-10
PL3221349T3 (pl) 2021-05-17
CY1123746T1 (el) 2022-05-27
US10160799B2 (en) 2018-12-25
JP6864763B2 (ja) 2021-04-28
MX2021014367A (es) 2022-01-06
AU2020227007A1 (en) 2020-09-17
CN107428820B (zh) 2022-03-22
HUE053239T2 (hu) 2021-06-28
ES2848376T3 (es) 2021-08-09
IL284250A (en) 2021-07-29
US20180142007A1 (en) 2018-05-24
AU2015348012B2 (en) 2020-07-02
RU2020126237A (ru) 2020-12-01
RS61431B1 (sr) 2021-03-31
CN107428820A (zh) 2017-12-01
US20190169276A1 (en) 2019-06-06
US11319363B2 (en) 2022-05-03
AU2015348012A1 (en) 2017-05-18
RU2017120688A (ru) 2018-12-19
JP2020141669A (ja) 2020-09-10
WO2016079597A1 (en) 2016-05-26
RU2017120688A3 (sl) 2019-07-17
JP2021119774A (ja) 2021-08-19

Similar Documents

Publication Publication Date Title
IL284250A (en) Tau antibodies of human origin in Alzheimer's disease
ZA201900373B (en) Anti-tim-3 antibodies
HK1243104A1 (zh) 抗fgfr2/3抗體及其使用方法
IL285722A (en) Methods for treating Alzheimer's disease
SG10201601719RA (en) Anti-LAG-3 Antibodies
GB201601073D0 (en) Antibodies
GB201621439D0 (en) IL-11Ra Antibodies
IL251837A0 (en) Anti-endoglin antibodies and their uses
GB201610044D0 (en) Antibodies
GB201603291D0 (en) Antibodies
GB201512596D0 (en) Biomolecules involved in Alzheimer's disease
PT3101132T (pt) Anticorpo humano anti-transtirretina
PL3180356T3 (pl) Ludzkie przeciwciało anty-fgfr4
IL264262A (en) Antibodies against interleukin 22 receptors
GB201616699D0 (en) Antibodies
IL267271A (en) Antibodies against il-5
SG11201610594WA (en) Anti-il4-il 13 bispecific antibodies
ZA201808317B (en) Anti-tnfrsf25 antibodies
IL272676B (en) Bispecific antibodies against il-4 and il-13
GB201622197D0 (en) Antibodies
GB201620414D0 (en) Antibodies
GB201615224D0 (en) Antibodies
GB201614863D0 (en) Alzheimer's disease
GB201612437D0 (en) Anti-lag-3 antibodies
GB201414038D0 (en) Alzheimer's disease